← Back to Analyst Consensus 
IRWD Buy
IRONWOOD PHARMACEUTICALS INC
Current Price —
Implied Upside —
Analysts 10
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Oct 29, 2026 (3 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Feb 26, 2026 | Citizens | maintain | Market Outperform → Market Outperform | $10 | 47% |
| Jan 5, 2026 | Wells Fargo | maintain | Equal-Weight → Equal-Weight | $5 | 54% |
| Jan 5, 2026 | Citizens | upgrade | Market Perform → Market Outperform | $8 | 47% |
| Nov 11, 2025 | Wells Fargo | maintain | Equal-Weight → Equal-Weight | $3 | 54% |
| Apr 15, 2025 | Wells Fargo | downgrade | Overweight → Equal-Weight | $1 | 54% |
| Apr 15, 2025 | Jefferies | downgrade | Buy → Hold | $0.7 | 52% |
| Apr 14, 2025 | Leerink Partners | maintain | Market Perform → Market Perform | $1 | 51% |
| Jan 30, 2025 | JMP Securities | maintain | Market Outperform → Market Outperform | $14 | 53% |
| Jan 22, 2025 | Craig-Hallum | maintain | Buy → Buy | $8 | 54% |
| Sep 9, 2024 | Leerink Partners | initiate | — → Market Perform | $5 | 51% |
| Aug 9, 2024 | Wells Fargo | maintain | Overweight → Overweight | $12 | 54% |
| Aug 9, 2024 | Craig-Hallum | maintain | Buy → Buy | $10 | 54% |
| May 10, 2024 | Craig-Hallum | maintain | Buy → Buy | $14 | 54% |
| Mar 1, 2024 | Wells Fargo | maintain | Overweight → Overweight | $14 | 54% |
| Feb 16, 2024 | Piper Sandler | maintain | Overweight → Overweight | $21 | 54% |
| Jan 17, 2024 | Craig-Hallum | initiate | — → Buy | $21 | 54% |
| Dec 14, 2023 | Wells Fargo | initiate | — → Overweight | $20 | 54% |
| Sep 28, 2023 | JMP Securities | initiate | — → Market Outperform | $22 | 53% |
| May 23, 2023 | Piper Sandler | maintain | Overweight → Overweight | $19 | 54% |
| Aug 16, 2022 | Wells Fargo | maintain | — → Equal-Weight | $13 | 54% |
| Apr 22, 2022 | Piper Sandler | initiate | — → Overweight | $16 | 54% |
| Oct 12, 2021 | Morgan Stanley | maintain | — → Equal-Weight | $14 | 54% |
| Jul 16, 2021 | Morgan Stanley | maintain | — → Equal-Weight | $12 | 54% |
| Feb 22, 2021 | Morgan Stanley | maintain | — → Equal-Weight | $11 | 54% |
| Feb 19, 2021 | Morgan Stanley | maintain | — → Equal-Weight | $11 | 54% |
| Nov 6, 2020 | Credit Suisse | maintain | — → Neutral | $12 | — |
| Nov 6, 2020 | Morgan Stanley | maintain | — → Equal-Weight | $12 | 54% |
| Sep 30, 2020 | Wells Fargo | downgrade | Overweight → Equal-Weight | $9 | 54% |
| Aug 7, 2020 | Morgan Stanley | maintain | — → Equal-Weight | $11 | 54% |
| Jul 15, 2020 | Morgan Stanley | maintain | — → Equal-Weight | $10 | 54% |
| Jun 1, 2020 | Credit Suisse | maintain | — → Neutral | $11 | — |
| May 11, 2020 | HC Wainwright & Co. | reiterate | — → Neutral | $11 | 44% |
| May 7, 2020 | Morgan Stanley | maintain | — → Equal-Weight | $11 | 54% |
| Apr 30, 2020 | Wells Fargo | maintain | — → Overweight | $15 | 54% |
| Apr 15, 2020 | Morgan Stanley | maintain | — → Equal-Weight | $12 | 54% |
| Mar 27, 2019 | Morgan Stanley | upgrade | Underweight → Equal-Weight | $14 | 54% |
| Feb 25, 2019 | HC Wainwright & Co. | upgrade | Sell → Neutral | $14 | 44% |
| Jan 24, 2019 | JP Morgan | upgrade | Underweight → Neutral | $13 | 54% |
| Nov 7, 2018 | JP Morgan | downgrade | Neutral → Underweight | $0 | 54% |
| Aug 9, 2018 | Wells Fargo | maintain | Outperform → Outperform | $23 | 54% |
| Jul 23, 2018 | HC Wainwright & Co. | initiate | — → Sell | $12.5 | 44% |
| Jul 18, 2018 | Cowen & Co. | downgrade | Outperform → Market Perform | $0 | — |
| May 31, 2018 | Wells Fargo | maintain | Outperform → Outperform | $20 | 54% |
| May 9, 2018 | Morgan Stanley | downgrade | Equal-Weight → Underweight | $0 | 54% |
| May 3, 2018 | Barclays | maintain | Equal-Weight → Equal-Weight | $20 | 53% |
| May 2, 2018 | Mizuho | upgrade | Neutral → Buy | $0 | 52% |
| Jan 5, 2018 | B of A Securities | downgrade | Buy → Underperform | $0 | 53% |
| Dec 6, 2017 | Mizuho | downgrade | Buy → Neutral | $0 | 52% |
| Nov 27, 2017 | Credit Suisse | initiate | — → Outperform | $19 | — |
| Jul 21, 2017 | JP Morgan | downgrade | Overweight → Neutral | $0 | 54% |
Price Target Trend
Apr 24, 2026 Latest: $6.1 Oct 24, 2026
EPS Estimates
0y $1.21
Lo: $1.20 Hi: $1.22
2 analysts ▲1
+1q $0.34
Lo: $0.34 Hi: $0.34
2 analysts 0q $0.31
Lo: $0.30 Hi: $0.32
2 analysts ▲1
+1y $1.50
Lo: $1.25 Hi: $1.82
3 analysts Cross-Platform Signals
No cross-platform signals in the last 90 days